Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Sunday, April 26

MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells (790)

Revital Aricha, Natalie Abramov, Jonathan Semo, Haggai Kaspi, Chaim Lebovits, Ralph Kern
First published April 14, 2020,
Revital Aricha
1BrainStorm Cell Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Abramov
1BrainStorm Cell Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Semo
1BrainStorm Cell Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haggai Kaspi
1BrainStorm Cell Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaim Lebovits
1BrainStorm Cell Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Kern
1BrainStorm Cell Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells (790)
Revital Aricha, Natalie Abramov, Jonathan Semo, Haggai Kaspi, Chaim Lebovits, Ralph Kern
Neurology Apr 2020, 94 (15 Supplement) 790;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: We evaluated the immunomodulatory properties of MSC-NTF cells and their effects on T and B regulatory cells.

Background: MSC-NTF cells (NurOwn®) are autologous, differentiated bone-marrow derived mesenchymal stem cells (MSC) that secrete neurotrophic factors (NTFs), regulatory miRNAs that demonstrate neuroprotection and immunomodulation in preclinical models and are currently under evaluation in phase 2 progressive MS and phase 3 ALS trials. Disordered T and B regulatory cell function has been implicated in the pathogenesis of ALS and MS. Furthermore, IL-10 production by regulatory B cells, may ‘regulate the regulators’, and has been viewed as a protective mechanism in ALS and MS animal models, possibly through effects on microglial networks.

Design/Methods: MSC-NTF cells were generated from healthy controls and were co-cultured with human peripheral blood mononuclear Cells (PBMC) or isolated B cells. The effect of MSC-NTF cells on proliferation of T or B cells and on induction of regulatory T or B cells was evaluated using flow cytometry. ELISA was used to measure secretion of different cytokines and IgM.

Results: MSC-NTF cells inhibited IFN-g and TNF-a secretion and CD4+/ CD8+ T cell proliferation when co-cultured with activated PBMCs, and induced CD4+CD25+FoxP3+ regulatory T cells. MSC-NTF cells did not affect B cells proliferation, however we observed that they induced CD24hiCD38hi regulatory B cells, stimulated IL-10 secretion, and inhibited B cell IgM secretion.

Conclusions: Neuroinflammation is a prominent pathological feature of ALS and progressive MS. Reduced T and B regulatory function may contribute to disease progression, and lower IL-10 levels may be associated with reduced ALS function and with higher disability and MRI lesion load in secondary progressive MS. The immunomodulatory properties of MSC-NTF cells, including their effects on T and B regulatory cells, combined with neuroprotective and repair mechanisms may extend the potential therapeutic benefits of MSC-NTF cells.

Disclosure: Dr. Aricha has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Abramov has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Semo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Kaspi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Lebovits has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Lebovits has received compensation for serving on the Board of Directors of BrainStorm Cell Therapeutics. Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics Ltd. BrainStorm Cell Therapeutics Ltd. employee

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (7)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise